The present application belongs to the technical field of battery materials, and in particular relates to a zinc diphosphide/zinc phosphate composite material, and a preparation method therefor and the use thereof. The zinc diphosphide/zinc phosphate composite material of the present application comprises zinc diphosphide, zinc phosphate, and a carbon-based material or a hybrid material thereof, wherein the zinc diphosphide is coated with the zinc phosphate and the carbon-based material or the hybrid material thereof. In the present application, amorphous zinc phosphate is utilized, and therefore the volume expansion of a battery during the processes of charging and discharging can be effectively relieved, and the cycling performance of the material can be improved; in addition, the carbon-based material or the hybrid material thereof coats the zinc diphosphide, and therefore the conductivity of the material can be improved, the rate capability can be enhanced, the problem of a reduction in conductivity due to the presence of zinc phosphate can be solved, and the battery has good rate capability and cycling stability. Moreover, by performing coating with the carbon-based material or the hybrid material thereof, the generation of white phosphorus during ball milling can be reduced, and the thermal stability of the material can be improved; and ball milling further promotes the connection of phosphorus-carbon covalent bonds, thereby improving the electrochemical performance while stabilizing the structure.
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
H01M 4/583 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx
H01M 4/13 - Electrodes for accumulators with non-aqueous electrolyte, e.g. for lithium-accumulatorsProcesses of manufacture thereof
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
2.
USES OF SPINEL-TYPE SINGLE CRYSTALS AS FERROELECTRICS AND RELAXOR FERROELECTRICS, ENERGY STORAGE MATERIAL AND RECHARGEABLE ENERGY STORAGE PRODUCT
Provided are the uses of spinel-type single crystals as ferroelectrics and relaxor ferroelectrics, which can be applied to energy storage materials, and rechargeable energy storage products. In respect of the use of spinel-type single crystals AB2O4 as ferroelectrics, in AB2O4, A is Ca, Sr, Ba, Ti, V, Cr, Mn, Fe, Co, Ni, Cu or Zn, and B is a transition metal element or a rare earth element. In respect of the use of spinel-type single crystals AB2O4 as relaxor ferroelectrics, in AB2O4, A is Sr, and B is Tb. The energy storage material comprises a spinel-type single crystal AB2O4. The rechargeable energy storage product comprises a spinel-type single crystal AB2O4. The spinel-type single crystals AB2O4 do not contain lead and exhibit ferroelectricity at room temperature, and individual spinel-type single crystals also exhibit a relaxation property, thus being capable of serving as novel lead-free relaxor ferroelectrics; the spinel-type single crystals are non-toxic and harmless, thereby being greener and more environmentally friendly.
C30B 13/24 - Heating of the molten zone by irradiation or electric discharge using electromagnetic waves
H01G 7/06 - Capacitors in which the capacitance is varied by non-mechanical meansProcesses of their manufacture having a dielectric selected for the variation of its permitivity with applied voltage, i.e. ferroelectric capacitors
Provided in the present application are a magnetic coupler and a wireless charging system. The magnetic coupler comprises a first transmitting coil, a second transmitting coil, a Litz wire and a receiver coil; the first transmitting coil and the second transmitting coil are coaxially arranged; the Litz wire is wound around the first transmitting coil and the second transmitting coil and is connected to the first transmitting coil and the second transmitting coil; when the magnetic coupler is in operation, the receiver coil is located within a magnetic field formed by the first transmitting coil and the second transmitting coil. The first transmitting coil and the second transmitting coil can be connected in series to ensure the axial misalignment resistance of the magnetic coupler, thus reducing the effect of misalignment on the coupling performance of the magnetic coupler; in operation, the first transmitting coil and the second transmitting coil form a charging area by means of superposition and the receiver coil of the magnetic coupler is placed within the charging area formed by the first transmitting coil and the second transmitting coil, thus ensuring the coupling capability of the magnetic coupler.
SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES (China)
Inventor
Xu, Chengzhong
Kong, Hui
Wang, Shuai
Li, He
Gao, Wei
Chen, Chaowei
Abstract
An autonomous driving test platform based on virtual-real integration technology, which platform belongs to the technical field of autonomous car testing. On the basis of cloud-edge-end three-level linkage, the platform combines real environment testing and sand table environment testing with virtual simulation technology. A vehicle-end real scene is an actual environment in which an autonomous vehicle is applied; and environmental information is collected, and feedback is provided for the environmental information and virtual-real fusion information. In a cloud-end virtual environment, in addition to building an autonomous driving virtual scene, data fusion is also performed on information from a real scene and a sand table scene, so as to generate virtual-real fusion data. A sand table environment is used as an edge portion to provide a relay space, which is used for bridging the cloud-end virtual environment to a vehicle-end real environment, digitally twinning the autonomous vehicle in the actual environment to a virtual simulation environment, and transmitting the virtual-real fusion information to the autonomous vehicle. The sand table environment, the virtual environment and the real environment fully interact with one another to implement data enhancement, thereby obtaining an optimal test effect.
USE OF KONJAC GLUCOMANNAN AND DERIVATIVE THEREOF, GLUCOMANNAN CAPRYLATE, NANOPARTICLES AND COATING OBTAINED FROM GLUCOMANNAN CAPRYLATE, PREPARATION METHOD FOR NANOPARTICLES, AND USE OF GLUCOMANNAN CAPRYLATE, NANOPARTICLES OR COATING
A use of konjac glucomannan and a derivative thereof, glucomannan caprylate, nanoparticles and a coating obtained from the glucomannan caprylate, a preparation method for the nanoparticles, and a use of the glucomannan caprylate, the nanoparticles or the coating, relating to the technical field of medicine and material chemistry. The konjac glucomannan and the derivative thereof can be used as extracellular matrix fillers, and glucomannan caprylate obtained by modifying the konjac glucomannan by means of an esterification reaction, and nanoparticles or a glucomannan caprylate coating further obtained from the glucomannan caprylate can both be used for preparing drugs or materials for regulating functions of nucleus pulposus cells, and in particular, can be used for preparing drugs or materials for relieving or treating intervertebral disc degeneration. The glucomannan caprylate has the characteristics of being non-toxic, easily available and highly histocompatible, and can be prepared into different dosage forms according to requirements. The present disclosure provides a novel idea to improve the microenvironment of intervertebral disc degeneration, and also provides a novel use of a biomaterial based on a polysaccharide derivative.
The present disclosure relates to the technical field of electronic circuits. Provided are a laser diode drive circuit, a laser transmitting circuit, and a LiDAR system. The laser diode drive circuit comprises a power supply input end, a control module and at least one group of drive switch units, wherein each group of drive switch units comprises a first switch unit and a second switch unit; the power supply input end is configured to connect to a first preset power source; the power supply input end is grounded by means of at least one laser diode to be driven, and the first switch unit and the second switch unit are connected in series to a power supply circuit of the laser diode; and a first input end of the control module is used for the input of a pulse signal, and a first output end and a second output end of the control module are respectively connected to a control end of the first switch unit and a control end of the second switch unit. By using the laser diode drive circuit provided in the present disclosure, the duration of a pulsed current in a laser diode can be controlled by means of the opening and closing of drive switch units, and thus an ultrashort laser pulse is realized.
The present disclosure relates to the technical field of skin hair regeneration, and in particular to glucohexaose and a preparation method therefor and an application thereof, and a hair regeneration preparation. The molecular structure of the glucohexaose is Man-Man-Man-Man-Glc-Glc. The gulcohexaose can specifically stimulate local macrophages to release a cytokine network mainly comprising CCL5 chemotactic factors, recruit lymphocytes mainly comprising regulatory T cells, induce an immune cascade reaction, regulate an immune microenvironment, activate rapid proliferation and differentiation of hair follicle stem cells at a hair follicle carina and at the lower end of the carina, remarkably promote periodic regeneration of hair follicles, and accelerate the process of driving the hair follicles to enter a growth period from a resting period, so as to achieve the effect of treating alopecia.
The present invention relates to the cross-technical fields of medicine, material chemistry, glycobiology and the like, in particular to a sulfonated hyaluronic acid compound, a preparation method therefor and an application thereof. The structural formula of the sulfonated hyaluronic acid compound is shown as in formula (I), wherein R is alkali metal cation or hydrogen; R1, R2, R3 and R4 are respectively independently selected from hydrogen or sulfonate ions and R1, R2, R3 and R4 cannot be hydrogen at the same time, 10
The present application relates to the technical field of edge computing, and, in particular, to a deep reinforcement learning-based task time optimization method in an edge computing network. The task time optimization method comprises: receiving a data acquisition task; according to the acquisition task, controlling first edge computing nodes to acquire surrounding data information, and generating a task; acquiring current operation state information of a first edge computing network; according to the operation state information, splitting the task into a first number of first tasks, and splitting the first tasks into a second number of sub-tasks having constraint relationships; according to the operation state information, on the basis of deep reinforcement learning, executing a corresponding scheduling decision on the sub-tasks; and according to the scheduling decision, issuing the sub-tasks to each of the corresponding edge computing nodes. The task execution time is optimized by means of splitting the tasks. The sub-tasks are issued to the corresponding edge computing nodes according to the scheduling decision so as to execute the plurality of sub-tasks in parallel, thereby improving task execution efficiency and increasing the utilization rate of the nodes in the edge computing network.
YUNNAN KEY LABORATORY OF PRIMATE BIOMEDICAL RESEARCH (China)
Inventor
Xu, Ren-He
Si, Wei
Yan, Yaping
Yang, Changkun
Li, Enqin
Abstract
Provided is an application of a sphere substance in the preparation of an intravenous injection, relating to the technical field of biomedicine. Intravenous injection of the sphere substance formed by MSC spheres or biomaterials is used as a new in-vivo delivery solution. Compared with the intravenous injection of discrete MSCs, the intravenous injection of the MSC spheres reduces the retention of the MSCs in lungs, and prolongs the-retention time and activity of the MSCs in blood and peripheral tissues, such that therapeutic effects for autoimmune diseases, inflammatory diseases, and tissues and organ injuries can be improved. In addition, the intravenous injection of biomaterial spheres is safe, can carry drugs, biologically active molecules or detection molecules, is applied to diagnosis and treatment of an animal disease model or a patient, is more effective and more durable than monomer molecules, and can also carry a variety of molecules to generate a synergistic effect.
The present application relates to the technical field of electric power systems, and provides a power grid system demand response control method and apparatus for resilience improvement, and a device. The method comprises: performing first adjustment on consumption power of demand-side load resources in a power grid system; determining a first adjustment deviation of the consumption power of the demand-side load resources having undergone the first adjustment; if the first adjustment deviation is greater than a preset power deviation threshold, performing second adjustment on the consumption power of the demand-side load resources according to a preset power state condition, such that the power state of the demand-side load resources after the second adjustment satisfies the preset power state condition; determining a second adjustment deviation of the consumption power of the demand-side load resources having undergone the second adjustment; and if the second adjustment deviation is still greater than the preset power deviation threshold, performing second adjustment on the consumption power of the demand-side load resources again according to the preset power state condition until the second adjustment deviation is less than or equal to the preset power deviation threshold. Thus, the resilience of demand response control of the power grid system is improved.
H02J 3/14 - Circuit arrangements for ac mains or ac distribution networks for adjusting voltage in ac networks by changing a characteristic of the network load by switching loads on to, or off from, network, e.g. progressively balanced loading
H02J 3/00 - Circuit arrangements for ac mains or ac distribution networks
H02J 3/46 - Controlling the sharing of output between the generators, converters, or transformers
12.
USE OF SIALYLTRANSFERASE INHIBITOR IN PREPARING MEDICAMENT FOR NEUTRALIZING ACIDIC TUMOR MICROENVIRONMENT
The present application relates to the field of tumor treatment technology, and in particular, to use of a sialyltransferase inhibitor in preparing a medicament for neutralizing an acidic tumor microenvironment. By providing the use of the sialyltransferase inhibitor in preparing the medicament for neutralizing the acidic tumor microenvironment, the sialyltransferase inhibitor can neutralize the acidic tumor microenvironment and establish an ecological barrier against tumor metastasis, thus providing a new way of preventing and treating tumors.
A use of a SMYD3-SHCBP1 inhibitor in combination with a PD1 inhibitor in preparation of a drug for treating cancer. It is determined via experiments that Smyd3-Shcbp1 acts as an initial tumorigenic signal that mediates the tumorigenic effects of Brca1 and ERα during pregnancy, before and during tumorigenesis in precancerous mammary epithelial cells. Moreover, it is proved that elevated Smyd3-Shcbp1 signaling can reprogram a tumor immunosuppressive microenvironment, and immunotherapeutic drug resistance develops after PD1 antibody treatment. Treatment with trametinib can reverse the expression of SMYD3-SHCBP1, the function of effector T cells can be enhanced by treatment using trametinib and a PD1 antibody in combination, and breast tumor with elevated SMYD3 and SHCBP1 are sensitive to ICB. The understanding of breast tumor progression is improved, and a new selection strategy is provided for breast cancer patients.
The present disclosure relates to the technical field of carbon nanomaterials, and provides near-infrared luminescent carbon dots and a preparation method therefor and an application thereof. The preparation of the near-infrared luminescent carbon dots comprises: carrying out oxidation treatment on raw material carbon dots in a polar aprotic organic solvent. The method is simple and easy to implement, the raw materials are cheap, large-scale batch preparation is easily achieved, and near-infrared luminescent carbon dots having photocatalytic properties can be prepared. Compared with raw carbon dots, the near-infrared luminescent carbon dots have defect-based enhanced near-infrared absorption and emission. Defects in the near-infrared luminescent carbon dots can capture excited electrons under irradiation of exciting light and promote photo-generated charge separation, so that holes having a strong oxidizing ability are formed in the carbon dots, and hydroxyl radicals can be generated in water. The present disclosure has good application prospects in the fields of fluorescence imaging, sterilization, etc.
The present disclosure belongs to the technical field of medicine. Provided in the present disclosure are a drug delivery system, and a preparation method therefor and the use thereof. The drug delivery system is a drug system in which a nano drug delivery material is loaded on a supramolecular-engineered frozen platelet, wherein the nano drug delivery material is a drug-loaded nano material modified by a first modifier; the supramolecular-engineered frozen platelet is an activated platelet which is modified by a second modifier and has been quickly frozen using liquid nitrogen; and the first modifier and the second modifier can be self-assembled and combined. The above-mentioned frozen platelet retains thrombotic targeting. After the frozen platelet loads the nano drug system via supramolecular system engineering, the thrombotic site-targeted delivery and rapid release of a drug can be achieved; and the present invention has high safety and specificity, thereby having relatively high broad-spectrum and promotion value. The drug delivery system has a simple preparation method, and can be used for preparing a drug for treating thromboembolic diseases.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
The present application relates to the technical field of wireless communications, and embodiments of the present application provide an active-passive hybrid reconfigurable intelligent surface-based wireless communication transmission method and a system. The active-passive hybrid reconfigurable intelligent surface-based wireless communication transmission method comprises: each terminal transmitting uplink pilot information to a base station and each active-passive hybrid reconfigurable intelligent surface; each active-passive hybrid reconfigurable intelligent surface selecting an active antenna unit to receive uplink pilot information; the base station obtaining all uplink channel information using a channel estimation algorithm; each active-passive hybrid reconfigurable intelligent surface performing configuration; the terminal transmitting an uplink signal; the base station performing joint processing on all the received uplink signals on the basis of the uplink channel information of the base station and the uplink channel information of the active antenna unit; the base station performing joint coding on downlink pilot frequency information or downlink data according to a target criterion and the uplink channel information of the base station, and performing joint transmission by means of the antenna array of the base station and the active antenna units of the active-passive hybrid reconfigurable intelligent surface. Transmission performance is improved on the basis of the active-passive hybrid reconfigurable intelligent surface.
Provided in the present disclosure are an egg white-carbon dot composite hydrogel, and a preparation method therefor and the use thereof, which belong to the technical field of biomedicine. The egg white-carbon dot composite hydrogel is formed from a carbon dot material and an egg white solution under the thermotropic effect, wherein a cross-linked carbon dot @ egg white three-dimensional network structure is formed by means of the interaction of the surface functional group of the carbon dot and the molecular chain opened under the thermal action of the protein molecule contained in egg white. Optionally, by means of external energy irradiation treatment, the ability of the surface functional group of the carbon dot to bind to the cross-linked protein peptide chain can be enhanced, and the mechanical strength of the hydrogel is improved. In the hydrogel provided in the present disclosure, the sensitization of egg white is greatly reduce, and nutritional ingredients and active substances of egg white are retained. The hydrogel has significant effects in human skin care, subcutaneous filling, attachment growth of culture cells, promotion of hair follicle regeneration, skin wound healing, etc. The hydrogel has a simple preparation process and a low cost, and has good application prospects.
A supramolecular gelated cell, a preparation method therefor, and use thereof. The supramolecular gelated cell comprises a cell and an intracellular hydrogel. The hydrogel is formed from a macrocyclic host molecule or a polymer modified by the macrocyclic host molecule and a polymer modified by a guest molecule by means of the interaction between the supramolecular host and guest. The supramolecular gelated cell can be used as a cell-like carrier to deliver a drug and can overcome, due to its not having cellular activity, the problems of drug phagocytosis and excretion during the targeted delivery of a cell carrier preparation. The supramolecular gelated cell has an intact cell membrane structure, solves the present problems of membrane protein loss and random arrangement of cell membrane-coated nanoparticles, and enhances the therapeutic function mediated by a cell membrane receptor protein.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
The present disclosure relates to the technical field of power electronics, and provides a direct-current step-down converter and a step-down device. The direct-current step-down converter comprises a voltage input module, a first inductor channel module, a second inductor channel module, and a voltage output module; the voltage input module is separately connected to the first inductor channel module and the second inductor channel module; the first inductor channel module and the second inductor channel module both comprise at least one switching tube, an inductor, and a flying capacitor; the first inductor channel module and the second inductor channel module are respectively used for switching the ON/OFF state of the switching tube under the control of an external control signal, reducing a voltage from the voltage input module on the basis of the inductor and the flying capacitor, and outputting the reduced voltage by means of the voltage output module. The present disclosure can have the advantage of large energy density when high conversion efficiency and better dynamic response are achieved within a wide output power range.
H02M 3/158 - Conversion of DC power input into DC power output without intermediate conversion into AC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only with automatic control of output voltage or current, e.g. switching regulators including plural semiconductor devices as final control devices for a single load
H02M 1/32 - Means for protecting converters other than by automatic disconnection
The present application relates to the technical field of integrated circuits, and provides an intelligent connecting line. The intelligent connecting line comprises a first serial communication interface, a first active adapter board, a transmission cable, a second active adapter board, and a second serial communication interface. The first serial communication interface is connected to the first active adapter board; the first active adapter board is connected to the second active adapter board by means of the transmission cable; and the second active adapter board is connected to the second serial communication interface. According to the present application, the voltage reduction requirement of the system on an electronic device can be reduced, the number and size of the required passive elements are reduced, and the conversion of a voltage domain is realized while the energy transmission is carried out.
A method for identifying deleterious genetic mutations, which method relates to the technical field of biomolecules. The method comprises: respectively converting, into density maps, obtained Ramachandran plots of wild-type proteins, benign protein variants, pathogenic protein variants, and proteins to be identified; dividing each density map into a plurality of regions, and by using the density maps of the benign protein variants, the pathogenic protein variants and the wild-type proteins as a reference, calculating an average density and a standard deviation of each region; if the deviation between the density of the proteins to be identified in each region and the average density of the region exceeds the standard deviation, marking the region as a density deviation region of the proteins to be identified; and on the basis of deviation data of the density deviation region of the proteins to be identified, determining mutations of the proteins to be identified. By means of the method, deleteriousness of unknown mutations can be identified with high throughput, thereby providing an approach for the study of gene mutations associated with cancer and other diseases, and diagnostic methods and therapeutic drugs therefor. The method has broad application prospects.
G16B 45/00 - ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
22.
DRUG FOR TREATMENT OF BREAST CANCER AND APPLICATION THEREOF
Provided herein is an application of an anti-PS antibody in combination with docetaxel and/or paclitaxel in a drug for the treatment of a breast cancer, belonging to the technical field of drugs. By means of the combination of the anti-PS antibody and docetaxel and/or paclitaxel, an expression phenotype of ATP11B low/Ptdss2 highis changed to the ATP11B high/Ptdss2 low to effectively overcome the metastasis process, which can not only reduce a primary tumor, but also greatly inhibit the metastasis of the primary tumor. Therefore, a new selective therapeutic strategy and drug are provided to prevent and treat breast cancers and their metastasis.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
Disclosed are a parallel multi-converter and a capacity design method therefor. A first output current model and a second output current model are generated by respectively acquiring electrical parameters of an inductive voltage source converter and a capacitive voltage source converter, and the first output current model and the second output current model are integrated under the same output current condition, so that it may be ensured that the inductive voltage source converter and the capacitive voltage source converter have the same current generating ability; meanwhile, a coupling inductance relationship between the inductive voltage source converter and the capacitive voltage source converter is combined to further obtain the optimal capacity value of the inductive voltage source converter and the optimal capacity value of the capacitive voltage source converter. Therefore, the L-VSC and the LC-VSC have the same current generating ability, and the multi-converter has lower total voltage capacity.
H02M 7/5387 - Conversion of DC power input into AC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only, e.g. single switched pulse inverters in a bridge configuration
H02M 7/48 - Conversion of DC power input into AC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode
24.
PLATINUM-BASED DRUG CARBON NANODOT, AND METHOD FOR PREPARING SAME AND CARBON NANODOT PROTEIN COMPOUND AND USE THEREOF
Provided are a platinum-based drug carbon nanodot and a method for preparing same and a carbon nanodot protein compound and use thereof. The platinum-based drug carbon nanodot comprises a carbon-based core having the characteristic of visible light absorption. The carbon-based core is combined with a tetravalent platinum element via a coordinate bond, and the platinum-based drug carbon nanodot can be reduced under light irradiation conditions to obtain a divalent platinum compound and a hydroxyl radical. The method for preparing the platinum-based drug carbon nanodot comprises subjecting a disubstituted aromatic compound and a tetravalent platinum compound to a solvothermal reaction to obtain the platinum-based drug carbon nanodot. Under irradiation of visible light, the carbon-based core generates hole-electron pairs. Excited-state electrons are captured by platinum (IV) to undergo a reduction reaction, which rapidly generates a Pt (II) compound with high cytotoxicity and a hydroxyl radical and reduces the pH value of cells and a tumor site, resulting in immunogenic death of cancer cells and activation of the anti-tumor immune response of the body as well while killing the cancer cells. The platinum-based drug carbon nanodot and the protein compound thereof of the present invention can serve as a high-efficiency photoactive anti-cancer drug for precision treatment of tumors.
The present disclosure provides the use of acetyltanshinone IIA in the preparation of medicament for treating lung cancer and medicament for treating lung cancer, which falls within the technical field of medicine. This protocol proposes the use of acetyltanshinone IIA in treating lung cancer, especially non-small cell lung cancer (NSCLC), which can antagonize primary and acquired drug resistance of NSCLC cells to epidermal growth factor receptor, tyrosine kinase inhibitor (EGFR TKIs), by using small molecule compound acetyltanshinone IIA. The present disclosure further identifies the molecular target of ATA and elucidates its mechanism of inhibiting the growth of drug-resistant NSCLC cells and tumors. The medicament containing acetyltanshinone IIA is expected to become a multi-target anticancer agent for treating TKI drug-resistant NSCLC.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
The present invention provides use of a cryptotanshinone substance (such as cryptotanshinone) in the preparation of a sensitizing drug for chemotherapy of malignant tumors with high NQO1 expression, and use of a combination of the cryptotanshinone substance (such as cryptotanshinone) and an NQO1-activating drug in the preparation of drugs for treating and/or preventing tumors with high NQO1 expression, resistance-reversing drugs and/or drugs for preventing prognostic recurrence. When the cryptotanshinone substance (such as cryptotanshinone) is used in combination with an NQO1 bioactivatable drug, cryptotanshinone can significantly increase the sensitivity of malignant tumor cells with high NQO1 expression to the NQO1 bioactivatable drug, improving the killing effect of the NQO1 bioactivatable drug on the malignant tumor cells, producing Coalism, efficacy-improving and synergistic effects, and thereby significantly reducing the use of the NQO1 bioactivatable drug.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Method of inhibiting a protein-protein interaction between Von Hippel-Lindau tumor-suppressor protein and hypoxia-inducible factor 1-alpha useful in the treatment of angiogenesis-related diseases and promoting wound healing.
An herbal composition including Fructus Terminaliae Chebulae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Corydalis Yanhusuo, Herba Polygoni Chinensis, Rhizoma Atractylodis Macrocephalae, and Semen coicis Lachryrna-jobi useful for treating diseases, such as inflammatory bowel disease, by increasing regulatory T cells in a subject in need thereof, methods for preparing of use and preparation thereof.
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
29.
USE OF AKT INHIBITOR IV IN PREPARATION OF REAGENT FOR INHIBITING BACTERIAL METABOLISM AND GROWTH
The present invention provides use of an AKT inhibitor IV in the preparation of a reagent for inhibiting bacterial metabolism and growth. The AKT inhibitor IV can be used as a new reagent for antibiotic effects, and can effectively inhibit the respiration of gram-negative bacteria and gram-positive bacteria, so that the effects of inhibiting the growth and metabolism of the gram-negative bacteria and gram-positive bacteria are achieved. In addition, the AKT inhibitor IV can inhibit the survival of the gram-negative bacteria, and can work synergistically with other antibiotics to achieve a better antibacterial effect.
The present disclosure discloses a fiber Bragg grating displacement sensor with positive and negative bidirectional measurement and free from vibration, which falls within the technical fields of fiber sensing and measurement monitoring, and aims to solve the problem that the measuring range of the existing fiber Bragg grating displacement sensor is positive, and the free end of the cantilever beam will generate vibration deformation, resulting in inaccurate displacement measurement. The sensor of the present disclosure has a positive and negative two-way displacement measurement range through the arrangement of a bidirectional measuring mechanism. In the measurement process, the cantilever beam of the vibration-avoiding mechanism is in an initial state of zero deformation, resulting in upper and lower bending deformation, so as to avoid the fatigue and failure problems caused by the cantilever beam and the fiber Bragg grating due to constant force.
G01B 11/16 - Measuring arrangements characterised by the use of optical techniques for measuring the deformation in a solid, e.g. optical strain gauge
G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis
A venom-based peptide and an application thereof, which relate to the technical field of biomolecules. The amino acid sequence of the peptide is represented by formula 1: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15-X16-X17-X18; X1, X5, X6, X9 and X11 are each selected from any one among A, V, L, I, M, F, W and P; X2, X3, X10, X15, X17 and X18 are each selected from any one among G, C, S, T, Y, N and Q; X7 is selected from D or E; X4, X8 and X16 are each selected from any one among K, R and H; and X12, X13 and X14 are each selected from any one among K, R, H, D and E. The peptide has the function of promoting self-renewal of human embryonic stem cells.
Disclosed are an attitude estimation method, a terminal, a system and a computer-readable storage medium. For the problem of attitude and sensor bias estimation, a cascade solution method is provided. The first part of the cascade is a Kalman filter applied to an LTV system, and the second part of the cascade is a nonlinear attitude observer built in SO(3). In the estimation process, only one constant inertial reference vector needs to be measured explicitly in body-fixed coordinates, and the complexity of the attitude estimation algorithm is greatly simplified by exploiting the geometric relationship between the inertial reference vector and the Earth angular velocity vector. At the same time, the time-varying characteristics of the implemented Kalman filter help to avoid the tedious empirical gain adjustment process that often relies on sets of piecewise constant gains, to improve the convergence speed of the algorithm.
Provided in the present disclosure are the use of acetotanshinone IIA in preparation of a drug for treating lung cancer and a drug for treating lung cancer. The present disclosure belongs to the technical field of drugs. The solution provides the uses of acetotanshinone IIA in the treatment of lung cancer, especially the treatment of non-small cell lung cancer (NSCLC), wherein acetotanshinone IIA, a small-molecular compound, can be used to resist primary and acquired drug resistances of NSCLC cells against epidermal growth factor receptors, namely tyrosine kinase inhibitors (EGFR TKIs). In the present disclosure, a molecular target of ATA is further determined, and the mechanism thereof for inhibiting drug-resistant NSCLC cells and tumor growth is also illustrated. A drug containing acetotanshinone IIA as an ingredient is expected to be developed into a multi-target anti-cancer agent for treating TKI drug-resistant NSCLC.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
The present disclosure relates to the technical field of biomedicine, and provided are a method for identifying apoptosis and necrosis and an application thereof. By means of two-photon microscopy, fluorescence spectroscopy, and fluorescence lifetime imaging microscopy, upon 1060 nm excitation of all apoptotic and necrotic cells, red fluorescence intensity is increased, and compared with living cells, apoptotic cells exhibit a longer lipofuscin fluorescence lifetime in lysosomes, but necrotic cells exhibit a shorter lipofuscin fluorescence lifetime. On the basis of a comparison of fluorescence lifetimes, a state change of cells after drug treatment can be revealed; said technique can be applied to drug screening, and can be influential in various fields of biomedical research and applications, such as mapping the heterogeneity of treatment responses in a tumor microenvironment, annotating single cell drug resistance in spatial transcriptomics, and capturing in vivo dynamics of cell death in embryo development.
The present invention relates to the technical field of bioengineering. Provided in the present disclosure are a composition based on a supramolecular artificial receptor cell, and a preparation method therefor and the use thereof. Provided in the present disclosure is a composition based on a supramolecular artificial receptor cell, which composition comprises a receptor cell with a host molecule embedded on a cell membrane, and a guest molecule derivative (capable of being used for the targeted modification of a target such as a pathogen or a target cell). The receptor cell can specifically recognize and clear a target without affecting the physiological function of the receptor cell by means of a supramolecular interaction between a host molecule and a guest molecule, so as to achieve a corresponding treatment effect. The preparation of the composition provided in the present disclosure is simple, rapid and mild in terms of conditions, and universal, providing a new idea for realizing targeted treatment.
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
242424242424244 do not contain lead and exhibit ferroelectricity at room temperature, and individual spinel-type single crystals also exhibit a relaxation property, thus being capable of serving as novel lead-free relaxor ferroelectrics; the spinel-type single crystals are non-toxic and harmless, thereby being greener and more environment-friendly.
A droplet generation method based on an electrowetting phenomenon, and the application thereof, which relate to the technical field of digital microfluidics. The droplet generation method based on an electrowetting phenomenon comprises: placing a mother droplet in an electrode area on a bottom plate of a digital microfluidic chip, and under a certain electric drive, the mother droplet being ejected outwards to generate a large number of tiny sub-droplets. A relatively large electrode having a relatively large current-carrying area is used, and a mother droplet is placed in an electrode area on a bottom plate, and since the droplet is completely placed in the electrode, an all-directional ejection can be generated. Therefore, the droplet generation method is a rapid, low-power-consumption and high-flux droplet generation method.
The present disclosure belongs to the technical field of analog circuits. Provided are a buck circuit and a power source management apparatus. The buck circuit comprises: a voltage input end, a voltage output end, a buck module and a control module, wherein the buck module comprises a plurality of switch assemblies, a first capacitor, a second capacitor and an inductor element; a first end of a first switch assembly is connected to the voltage input end, a second end of the first switch assembly is connected to a first end of a third switch assembly, a second end of the third switch assembly is connected to a first end of a fifth switch assembly, and a second end of the fifth switch assembly is connected to the voltage output end; and an output end of the control module is respectively connected to a control end of each switch assembly. By means of the present disclosure, relatively few circuit elements are used, such that the complexity of a circuit system can be reduced, and the bucking of power source circuits in relatively small portable and wearable electronic devices can be realized.
H02M 3/07 - Conversion of DC power input into DC power output without intermediate conversion into AC by static converters using resistors or capacitors, e.g. potential divider using capacitors charged and discharged alternately by semiconductor devices with control electrode
H02M 1/088 - Circuits specially adapted for the generation of control voltages for semiconductor devices incorporated in static converters for the simultaneous control of series or parallel connected semiconductor devices
39.
CERAMIC OXIDE SOLID-STATE ELECTROLYTE AND PREPARATION METHOD THEREFOR
The present disclosure relates to the technical field of electrolytes, and provides a ceramic oxide solid-state electrolyte and a preparation method therefor. The preparation method for a ceramic oxide solid-state electrolyte implements the preparation by means of main raw materials and an additive, and comprises: mixing and calcining main raw materials to obtain intermediate powder, and mixing the intermediate powder with an additive and sintering same, wherein the additive is fluoride, and the mass ratio of the additive to the intermediate powder is 0.1-10:100. After the main raw materials are calcined, the additive is introduced for sintering, such that the requirement for the accuracy of raw material weighing and the process cost in ball milling are reduced, and more importantly: by selecting the type of the additive and adjusting the amount of additive usage, the purpose of significantly improving the ionic conductivity can be achieved while adding an extremely small proportion of fluoride. The present invention is a simple and efficient process.
The present disclosure relates to the technical field of skin hair regeneration, and in particular to glucohexaose and a preparation method therefor and an application thereof, and a hair regeneration preparation. The molecular structure of the glucohexaose is Man-Man-Man-Man-Glc-Glc. The gulcohexaose can specifically stimulate local macrophages to release a cytokine network mainly comprising CCL5 chemotactic factors, recruit lymphocytes mainly comprising regulatory T cells, induce an immune cascade reaction, regulate an immune microenvironment, activate rapid proliferation and differentiation of hair follicle stem cells at a hair follicle carina and at the lower end of the carina, remarkably promote periodic regeneration of hair follicles, and accelerate the process of driving the hair follicles to enter a growth period from a resting period, so as to achieve the effect of treating alopecia.
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
Disclosed is a method for preparing supramolecular cell-based carrier, which relates to the technical fields of supramolecular chemistry, supramolecular materials and cell preparations. Host-guest interactions mediated supramolecular cell-based carriers can achieve targeted delivery based on cell physiological functions, and have high biocompatibility, physiological barrier permeability, and targeting delivery efficiency. It does not require covalent bond modification on the cell surface, and has no effect on the physiological functions of transporting cells. The preparation method of supramolecular cell-based carrier provided by the present application has the advantages of simple and fast construction process, mild conditions and universal applicability, and the method has bio-orthogonality. In addition, a drug loading system is also provided, which can realize drug loading for targeted therapy.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
42.
NANOEMULSION PREPARATION FOR TREATING MIGRAINES, AND PREPARATION METHOD THEREFOR AND USE THEREOF
A method for preparing a nanoemulsion preparation for treating migraines comprises the following steps: selecting Angelicae sinensis radix and Chuanxiong rhizoma as raw materials, and extracting volatile oil by means of a supercritical extraction method, wherein the weight ratio of Angelicae sinensis radix to Chuanxiong rhizoma is 1:0.5-2; and selecting chitosan and alginate, loading the volatile oil on same by means of a single-emulsion solvent evaporation method to complete the preparation of a nanoemulsion, wherein the particle size of the nanoemulsion preparation is 200-300 nm. Further disclosed are a nanoemulsion preparation prepared by the above method and used for treating migraines, and the use of the nanoemulsion preparation prepared by the above method and used for treating migraines in the preparation of a food rproduct or a drug for treating migraines.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
44.
APPLICATIONS OF BMS-833923 AND DERIVATIVE THEREOF, AND DRUG
The present invention relates to technical field of antibiotics, and provides applications of BMS-833923 and a derivative thereof, and a drug. The BMS-833923 and the derivative thereof can be used as a colistin adjuvant to jointly inhibit or eliminate gram-negative bacteria, and can also independently inhibit or eliminate gram-positive bacteria. The gram-negative bacteria may comprise Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and pan-drug resistant strains BAA-1800, BAA-1794, and BAA-1792, and the gram-positive bacteria may comprise at least one of Staphylococcus aureus and Bacillus subtilis. The BMS-833923 and the derivative thereof are used as the colistin adjuvant, so that the treatment index of the colistin can be effectively expanded, and the low-toxic and non-toxic dosage of colistin can be allowed to be clinically used for effective treatment of drug-resistant bacterial infection.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Provided in the present disclosure are a supramolecular nanoparticle precursor coated with bacterial outer membrane vesicles, the use and a drug delivery system, which relate to the technical fields of supramolecular chemistry, supramolecular materials and cell preparations. The supramolecular nanoparticle precursor based on the coating with bacterial outer membrane vesicles can specifically recognize immune cells in vivo, and further construct an intracellular nanoparticle aggregate mediated by host-guest interaction. An endogenous immune cell carrier can respond to the inflammatory characteristics of lesion tissues (such as tumors), achieve the hitchhiking delivery of intracellular nanoparticle aggregates, and inhibit the exocytosis phenomenon of immune cells. A method for preparing the in vivo (and intracellular) supramolecular nanoparticle assembly mediated by host-guest interaction provided in the present disclosure has the advantages of a simple, rapid and universal preparation process, and can overcome the challenges faced by the construction of a cell carrier preparation and an in-vivo delivery process. In addition, further provided is a drug delivery system, which can achieve drug delivery of targeted drug therapy.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY (China)
Inventor
Deng, Chuxia
Liu, Tzu Ming
Xing, Fuqiang
Wang, Guanyu
Abstract
Provided are a method for screening a drug and a method for culturing a three-dimensional tumor slice model, which relate to the field of biomedicines. A method for culturing a three-dimensional tumor slice model is established, and in combination with label-free technology and/or a time-lapse imaging method for an apoptosis reporter substance, high-throughput screening of a drug is implemented, and a high-efficiency drug for a specific cancer sample is obtained within one week. In the culture of the three-dimensional tumor slice model, immune components of an original tumor are completely retained, allowing for the successful implementation of an immune checkpoint blocking test by using an immune checkpoint inhibitor. Said technology provides a cheap, fast, and simple platform for anti-cancer drug discovery and accelerates precise anti-cancer treatment.
The use of FGFR and a related signaling pathway inhibitor thereof in the preparation of a drug for treating an FGFR2 mutant tumor. An FGF/FGFR2 signal drives formation of triple negative breast cancer and promotes an epithelial-to-mesenchymal transition along with FGFR2-STAT3; it has also been found that FGFR2 accelerates formation of a tumor by inhibiting BRCA1 by means of MAPK-YY1. In addition, FGFR2 also regulates expression of PD-L1 by means of STAT3-MAPK.
Provided are an inducer, a macrophage and the use thereof. By means of the inducer, a monocyte is cultured and induced using a composition composed of osteopontin (OPN) and other cytokines, so that a macrophage with a strong repair function and used for tissue wound repairing, wound healing and tissue regeneration can be formed.
An artificial edible bird's nest (EBN) and a preparation method therefor, which relate to the technical field of food science, tissue engineering and biomaterial overlap. The preparation method for artificial EBN comprises: solidifying animal-derived gelatin mixed with epithelial cells into a gelatinous culture layer, the epithelial cells comprising salivary gland epithelial cells; constructing a collection layer of ion-exchange macromolecular network structures from polysaccharides and edible gelatin, the polysaccharides comprising positively charged polysaccharides and negatively charged polysaccharides; and placing the culture layer above the collection layer, and immersing the culture layer in a culture medium, allowing the collection layer to collect cell secretions overflowing from the culture layer. The artificial EBN is obtained by using preparation methods such as the foregoing. Artificial breeding of swallows is not involved in the preparation, damage to wild swallows or other natural resources is not involved, and the nutritional composition of the obtained artificial EBN is not inferior to that of natural EBN, and the artificial EBN is almost free of substances that are harmful to the human body, such as nitrite, heavy metal ions and fungi.
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
A23L 29/30 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing carbohydrate syrupsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugarsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugar alcohols, e.g. xylitolFoods or foodstuffs containing additivesPreparation or treatment thereof containing starch hydrolysates, e.g. dextrin
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
51.
APPLICATION OF SPHERE SUBSTANCE IN PREPARATION OF INTRAVENOUS INJECTION
YUNNAN KEY LABORATORY OF PRIMATE BIOMEDICAL RESEARCH (China)
Inventor
Xu, Ren-He
Si, Wei
Yan, Yaping
Yang, Changkun
Li, Enqin
Abstract
Provided is an application of a sphere substance in the preparation of an intravenous injection, relating to the technical field of biomedicine. Intravenous injection of the sphere substance formed by MSC spheres or biomaterials is used as a new in-vivo delivery solution. Compared with the intravenous injection of discrete MSC, the intravenous injection of the MSC spheres reduces the retention of the MSC in lungs, and prolongs the retention time and activity of the MSC in blood and peripheral tissues, such that therapeutic effects for autoimmune diseases, inflammatory diseases, and tissue and organ injuries can be expected to be improved. In addition, the intravenous injection of biomaterial spheres is safe, can carry drugs, biologically active molecules or detection molecules, is applied to diagnosis and treatment of an animal disease model or a patient, is more effective and more durable than monomer molecules, and can also carry a variety of molecules to generate a synergistic effect. Therefore, a new use approach and a new research method are provided for clinical application of cells and biomaterials.
Provided are a quantum dot-enhanced tumor inactivated vaccine, a preparation method, and an application. Under the action of heat, a spatial structure of a protein molecule chain on a tumor cell is opened, the protein molecule chain is loosened and a gap is formed, a small quantum dot enters into a spatial conformation of the protein, and a hydrogen bond is formed by means of a functional group at the surface of the quantum dot and a group on the protein molecule chain, and thereby a quantum dot modified inactivated cancer cell complex is formed. The provided inactivated vaccine preserves the primary structure of a cancer cell antigen, i.e. an amino acid sequence is not destroyed, while increasing a specific anti-tumor immune response of capture, presentation, and induction of the cancer cell antigen protein by the immune system. The provided quantum dot-enhanced cancer cell inactivated vaccine can be applied in personalized cancer immunotherapy.
Provided is a full-target antigen-presenting cell (APC) tumor vaccine, and a preparation method therefor and an application thereof. The preparation method for the full-target APC tumor vaccine comprises: performing co-incubation of a quantum dot-modified tumor cell and an immature APC, wherein the quantum dot-modified tumor cell is obtained by linking a quantum dot to a protein molecular chain of a tumor cell by means of a hydrogen bond. By means of the co-incubation of the quantum dot-modified tumor cell and the immature APC, the immature APC (e.g., an MP or a DC) can be converted from an immature state to a hyperactivated state, such that uptake of tumor antigens by the APC is enhanced, MHC molecule expression is significantly upregulated, and the antigen presenting efficiency is improved.
A quantum dot modified protein vaccine and a preparation method therefor and an application thereof, relating to the field of nanomaterials and biomedicines. Raw materials of the quantum dot modified protein vaccine comprise quantum dot particles and antigen protein, the surfaces of the quantum dot particles comprise biocompatible functional groups, and the antigen protein and the functional groups act to enable the protein to be wound on the surfaces of the quantum dot particles under the action of non-covalent bonds. The antigen protein is modified by means of the quantum dots, a spatial conformation of the antigen protein can be changed, the immunogenicity of normal protein is remarkably enhanced due to these conformation modifications, dysfunction of immunosuppressive protein on cancer cells is caused, and the specific recognition probability can be enhanced. Such a quantum dot modified protein vaccine can greatly improve the immunogenicity of protein, and thus has better immune activation characteristics. The quantum dot modified protein vaccine is simple in preparation method, and is mild in operation conditions. The obtained quantum dot modified protein vaccine can be applied to personalized immunotherapy of cancers.
The present disclosure provides a control system of a buck converter, relating to the field of Internet of Things. The control system of a buck converter provided in an embodiment of the present disclosure includes a first control module, a second control module, and a mode selector. The first control module is turned on and the second control module is turned off through an analog current sensor in the mode selector when an IoT device switches from a transmission mode to a sleep mode or a standby mode, so that the first control module outputs a first voltage pulse to the driving and level shifter module, wherein a frequency of the first voltage pulse is determined by a frequency of a first clock in the first control module, and a width of the first voltage pulse is determined by a frequency of a second clock in the first control module.
H02M 3/158 - Conversion of DC power input into DC power output without intermediate conversion into AC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only with automatic control of output voltage or current, e.g. switching regulators including plural semiconductor devices as final control devices for a single load
Disclosed are a lipid substance additive, a cell culture medium containing same, and the use thereof. The lipid substance additive is obtained by means of dissolving lipid substances in a solvent, wherein the lipid substances comprise arachidonic acid, cholesterol, dl-α-tocopheryl acetate, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitic acid, palmitoleic acid and stearic acid. Furthermore, the lipid substance additive at least does not contain Tween 80.
Provided are an application of thyroxine in preparation of a drug for treating delayed embryonic development or incomplete embryonic development, an application of the thyroxine in preparation of a reagent for promoting growth, metabolism, and differentiation of pluripotent stem cells, a culture medium for culturing pluripotent stem cells, an application of the culture medium, and a method for culturing pluripotent stem cells.
A method for identifying deleterious genetic mutations, which method relates to the technical field of biomolecules. The method comprises: respectively converting, into density maps, obtained Ramachandran plots of wild-type proteins, benign protein variants, pathogenic protein variants, and proteins to be identified; dividing each density map into a plurality of regions, and by using the density maps of the benign protein variants, the pathogenic protein variants and the wild-type proteins as a reference, calculating an average density and a standard deviation of each region; if the deviation between the density of the proteins to be identified in each region and the average density of the region exceeds the standard deviation, marking the region as a density deviation region of the proteins to be identified; and on the basis of deviation data of the density deviation region of the proteins to be identified, determining mutations of the proteins to be identified. By means of the method, deleteriousness of unknown mutations can be identified with high throughput, thereby providing an approach for the study of gene mutations associated with cancer and other diseases, and diagnostic methods and therapeutic drugs therefor. The method has broad application prospects.
Provided are a method and a drug for inducing the differentiation of a stem cell into a mesoderm lineage or a trophoblast lineage, the method and drug belonging to the technical field of regulation of the differentiation of a human pluripotent stem cell into a mesoderm or trophoblast cell. The method for differentiation into a mesoderm lineage comprises inducing the differentiation of a stem cell into a mesoderm lineage by using a differentiation culture medium containing a PKC inhibitor in the presence of BMP4. The method improves the stability of differentiation, and can maintain the specific differentiation of a germ layer in the absence of exogenous FGF2 or endogenous WNT. The method for differentiation into a trophoblast lineage comprises inducing the differentiation of a stem cell into a trophoblast lineage by using a differentiation culture medium containing a PKC activator or a DGK inhibitor. The method induces the differentiation of stem cells into trophoblasts in an accelerated manner by means of using a PKC activator and a DGK inhibitor in a spontaneous differentiation platform without BMP4.
The present disclosure discloses use of mesenchymal stem cells in preparation of a formulation for promoting fat transplantation, relating to the field of biotechnologies. The inventors found through research that compared with MSCs derived from somatic cells, MSCs derived from human pluripotent stem cells have more stable quality, are not affected by donor's physical quality, disease and treatment process, and can promote fat transplantation by enhancing tissue remodeling, angiogenesis and adipose cell survival and decreasing tissue fibrosis.
Provided are a supramolecular cell carrier, a drug carrying system and a preparation method therefor, relating to the technical field of supramolecular chemistry, supramolecular materials and cell preparations. The supramolecular cell carrier constructed on the basis of the supramolecular host-guest interaction can achieve a targeted delivery effect based on cell functions, and has high biocompatibility, high physiological barrier permeability and high targeting ability. Covalent bond modification on cell surface is not needed, and the physiological function of a modified cell may not be affected. The provided preparation method for the supramolecular cell carrier has the advantages of simple preparation process, rapidness, mild conditions and universality, and has biological orthogonality. Further provided is a drug carrying system, which can achieve drug carrying of targeted drug therapy.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A venom-based peptide and an application thereof, which relate to the technical field of biomolecules. The amino acid sequence of the peptide is represented by formula 1: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12 -X13-X14-X15-X16-X17-X18; X1, X5, X6, X9 and X11 are each selected from any one among A, V, L, I, M, F, W and P; X2, X3 , X10, X15, X17 and X18 are each selected from any one among G, C, S, T, Y, N and Q; X7 is selected from D or E; X4, X8 and X16 are each selected from any one among K, R and H; and X12, X13 and X14 are each selected from any one among K, R, H, D and E. The peptide has the function of promoting self-renewal of human embryonic stem cells.
Disclosed in the present invention is an application of a mesenchymal stem cell (MSC) in preparing a preparation for promoting fat grafting, relating to the technical field of biology. After research of the inventor, it is found that compared with MSCs derived from somatic cells, the quality of MSCs derived from human embryonic stem cells is more stable, and is not affected by physical fitness, disease, and a treatment process of a donor, and fat grafting can be promoted by enhancing tissue remodeling, angiogenesis, and adipocyte survival, and reducing tissue fibrosis.
Disclosed is a use of artemether in preventing and treating Alzheimer's disease. Artemether is a safe and effective compound for treatment against malaria. Artemether activates an AMPK signaling pathway in the brain of a transgenic mouse model of Alzheimer's disease, improves learning and memory abilities in the mouse model, reduces neuron apoptosis in the brain, improves function of choline acetyltransferase, inhibits activity of glial cells, and reduces amyloid plaque deposition, neurofibrillary tangle, and neuron loss, thereby providing an experimental basis for clinical research on the treatment of Alzheimer's disease.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
An exemplary embodiment of the present invention is a wireless power transmission circuit that provides power to a load of variable resistance with an alternating current (AC) power source induced at a secondary coil in a secondary side of the circuit by a primary coil in a primary side of the said circuit. The wireless power transmission circuit includes a switch-controlled capacitor (SCC) and a semi-active rectifier (SAR). The SCC connects to the AC power source. The SCC includes a first capacitor connected in parallel with two electrically controllable switches in series. The SAR connects to output of the SCC for rectifying the output of the SCC, wherein the SAR comprises a bridge circuit that includes two electrically controllable switches. A control angle of the SCC and a conduction angle of the SAR are regulated to provide a load impedance that matches the impedance of the coils.
H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
H02J 50/12 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling of the resonant type
H02J 7/02 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries for charging batteries from AC mains by converters
H02M 7/219 - Conversion of AC power input into DC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only in a bridge configuration
H02M 1/08 - Circuits specially adapted for the generation of control voltages for semiconductor devices incorporated in static converters
66.
Apparatus and methods of generating 4-dimensional computer tomography images
The present disclosure provides a system comprising a SPECT or PET device; a CT device; and a computer comprising memory and a processor in communication with the memory, the memory comprising a computer application program for a method of performing dosimetric analysis of an organ. The computer application program is executable by the processor to perform the method. The method comprising receiving single photon emission computed tomography (SPECT) or positron emission tomography (PET) images at time instances, the SPECT or PET images relating to the organ. The method then receives a computed tomography (CT) image at one of the time instances, the CT image relating to the organ. Virtual CT images are then generated at the other time instances based on the received SPECT or PET images and the CT image. An absorbed dose of ionising radiation on the organ can then be measured based on the received SPECT or PET images, the received CT image, and the generated virtual CT images. The method generates the virtual CT images using any one of: SPECT to SPECT (or PET to PET) registration, CT to SPECT (PET) registration, and SPECT (PET) to CT registration.
Provided is a method for assessing cytotoxicity of a cytotoxic cell that includes culturing a plurality of the cytotoxic cells with a plurality of target cells in a microfluidic device and determining whether the cytotoxic cells have a cytotoxic effect on the target cells, such as by determining a cell count and/or status of the cytotoxic cells and/or the target cells. A kit and a system for use in the aforementioned method are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
68.
Use of scutellarin in a medicament and a modulator for preventing or treating diseases, medicament, and modulator
The present disclosure discloses use of scutellarin in a medicament and a modulator for preventing or treating diseases, a medicament, and a modulator, which is related to the technical field of medicine. The present disclosure discloses use of scutellarin in the preparation of a medicament for preventing or treating a disease caused or mediated by interaction between TNF and TNFR2. The research in the present disclosure has shown that scutellarin is capable of selectively inhibiting TNF-induced death of WEHI-13VAR cells and significantly inhibiting TNF-induced proliferation of Tregs, accompanied with down-regulation of TNFR2 and Foxp3 expression in Tregs. This indicates that scutellarin can be used to treat or prevent relevant diseases caused or mediated by the interaction between TNF and TNFR2, and the present disclosure provides a new idea or means for preventing or treating relevant diseases caused or mediated by the interaction between TNF and TNFR2.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
Provided is an apparatus, system and method for on-chip microfluids dispensing. The apparatus comprising a substrate; a plurality of first electrodes arranged one next to another on the substrate; a dielectric layer above and enclosing the plurality of first electrodes; and a second electrode on the substrate, wherein each of the plurality of first electrodes is in electric communication with a respective first driving signal input; wherein the second electrode is in electric communication with a second driving signal input; wherein the plurality of first electrodes define a continuous fluid path along a longitudinal direction for retaining microfluids, and wherein the second electrode is arranged within the continuous fluid path and defines a jetting position and an adjacent mixing position within the continuous fluid path.
st order accumulator, an exponential accumulator, and a decimator. The linear-exponential IADC is configured to operate with a linear phase for suppressing the thermal noise and an exponential phase for boosting the SQNR.
H04B 1/00 - Details of transmission systems, not covered by a single one of groups Details of transmission systems not characterised by the medium used for transmission
H03M 1/08 - Continuously compensating for, or preventing, undesired influence of physical parameters of noise
71.
USE OF ARTEMETHER IN PREVENTING AND TREATING ALZHEIMER'S DISEASE
Disclosed is a use of artemether in preventing and treating Alzheimer's disease. Artemether is a safe and effective compound for treatment against malaria. Artemether activates an AMPK signaling pathway in the brain of a transgenic mouse model of Alzheimer's disease, improves learning and memory abilities in the mouse model, reduces neuron apoptosis in the brain, improves function of choline acetyltransferase, inhibits activity of glial cells, and reduces amyloid plaque deposition, neurofibrillary tangle, and neuron loss, thereby providing an experimental basis for clinical research on the treatment of Alzheimer's disease.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Methods for the early sensing of tissue ischemia and/or infarctions within organs using the spectroscopic features of serum luminescence include (i) isolating serum from a blood sample, (ii) directing an excitation light at the serum, (iii) receiving an endogenous serum chromophore emission light from the excited serum, and (iv) determining a presence of an ischemic condition based on the intensity of the endogenous serum chromophore emission light. Methods of detecting organ dysfunction can include transmitting excitation light to luminal contents of a mammalian blood vessel comprising trace amounts of exogenous chromophores administered to the subject mammal via the circulatory system. Transdermal luminescence measurements from the trace amounts of exogenous chromophores can then be used to determine organ dysfunction. Such methods enable routine monitoring of blood luminescence to bridge the diagnosis gap between sensitive symptom diagnosis and specific marker diagnosis, resulting in an effective early screening modality.
Provided is an apparatus, system and method for on-chip microfluids dispensing. The apparatus comprising a substrate; a plurality of first electrodes arranged one next to another on the substrate; a dielectric layer above and enclosing the plurality of first electrodes; and a second electrode on the substrate, wherein each of the plurality of first electrodes is in electric communication with a respective first driving signal input; wherein the second electrode is in electric communication with a second driving signal input; wherein the plurality of first electrodes define a continuous fluid path along a longitudinal direction for retaining microfluids, and wherein the second electrode is arranged within the continuous fluid path and defines a jetting position and an adjacent mixing position within the continuous fluid path.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of tumor amongst all human cancers due to late diagnosis and resistant to treatment with chemotherapy and radiation. Preclinical and clinical studies have revealed that ErbB family for example epidermal growth factor receptor (EGFR) is a validated molecular target for pancreatic cancer prevention and therapy. The ErbB signaling cascade is regulated by a member of the ADAM (a disintegrin and metalloprotease) family, namely ADAM17, by enzymatic cleavage of precursor ligands into soluble cytokines and growth factors. Mouse genetic studies have demonstrated that ADAM17 is required for PDAC development. In this study, we evaluated the anti-tumor effects of A9(B8) IgG—the first specific ‘human and mouse cross-reactive’ ADAM17 inhibitory antibody on pancreatic malignant transformation. We found that inhibition of ADAM17 with A9(B8) IgG efficiently suppressed the shedding of ADAM17 substrates both in vivo and in vitro. Furthermore, we demonstrated that administration of A9(B8) IgG significantly suppressed motility in human pancreatic cancer cells and also significantly delayed tumorigenesis in the Pdx1Cre;KrasG12D;Trp53fl/+ PDAC mouse model. Inhibition of ADAM17 with A9(B8) IgG particularly affected the progression of pre-invasive pancreatic lesions to advanced PDAC in mice. Taken together, the preclinical data presented here will provide a starting point for clinical applications of ADAM17 targeted therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Provided is a digital microfluidic device for quick polymerase chain reaction. The digital microfluidic device includes an enclosed chamber for holding droplets comprising PCR mixtures. The chamber has an upper layer and a lower layer, which provide a top heater and a bottom heater contained in a thermal electrode respectively to form dual heaters. The lower layer further has an array of electrodes and a dielectric layer, e.g. Norland Optical adhesive 61, coating thereon. Such arrangement of the digital microfluidic device allows quick and homogeneous heating of droplets to lower the heating voltage, shorten the reaction time, and prevent the dielectric layer from breakdown during the thermal cycle.
A novel piezo-driven cell injection system with force feedback overcomes the unsatisfied force interaction between the pipette needle and embryos in conventional position control. By integrating semiconductor strain-gage sensors for detecting the cell penetration force and the micropipette relative position in real time, the developed cell microinjection system features high operation speed, confident success rate, and high survival rate. The effectiveness of the developed cell injection system is experimentally verified by penetrating zebrafish embryos. The injection of 100 embryos are conducted with separate position control and force control. Results indicate that the force control enables a survival rate of 86%, which is higher than the survival rate of 82% produced by the position control in the same control environment. The experimental results quantitatively demonstrate the superiority of force control over conventional position control for the first time.
G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
H02N 2/02 - Electric machines in general using piezoelectric effect, electrostriction or magnetostriction producing linear motion, e.g. actuatorsLinear positioners
A method for detecting deoxyribonucleic acid (DNA), comprising the following steps: obtaining a melting time-fluorescent brightness curve of DNA of a control group; obtaining a melting time-fluorescent brightness curve of DNA of a detection sample; and comparing the melting time-fluorescent brightness curve of DNA of the control group to the melting time-fluorescent brightness curve of the DNA of the detection sample, thereby obtaining a detection result. The control group is a blank control group or standard DNA or DNA of a known mutation type.
A flipping-capacitor rectifier circuit that enhances an output power of a piezoelectric energy harvester (PEH). The flipping-capacitor rectifier circuit includes a flipping capacitor, a plurality of switches, and an active rectifier. The flipping capacitor is connected in parallel with the PEH and forms at least three reconfiguration phases by turning on one or more of the switches. The active rectifier connects with the flipping capacitor in parallel and rectifies an AC voltage of the PEH. The flipping capacitor flips a voltage across a capacitor of the PEH to enhance the output power of the PEH by extracting power from the capacitor of the PEH.
H01L 41/04 - SEMICONDUCTOR DEVICES; ELECTRIC SOLID STATE DEVICES NOT OTHERWISE PROVIDED FOR - Details thereof - Details of piezo-electric or electrostrictive elements
H02M 7/06 - Conversion of AC power input into DC power output without possibility of reversal by static converters using discharge tubes without control electrode or semiconductor devices without control electrode
H02M 7/217 - Conversion of AC power input into DC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only
79.
Method of differentiating pluripotent stem cells into mesenchymal stem cells under 3D spheroidal culture conditions
A method of differentiating pluripotent stem cells into mesenchymal stem cells, a culture medium used in the method of differentiating pluripotent stem cells into mesenchymal stem cells and a method of performing tissue and organ regeneration by using the mesenchymal stem cells obtained by differentiation using the method of differentiating pluripotent stem cells into mesenchymal stem cells are provided. The method of differentiating pluripotent stem cells into mesenchymal stem cells comprises differentiating, completely under 3D suspension conditions, pluripotent stem cells into trophoblast-like cells using BMP4 and A8301, and then differentiating the trophoblast-like cells into mesenchymal stem cells. Neither of two differentiation processes needs passaging or replacement of a culture container.
Bidirectional wireless power transfer (WPT) manages to provide a first aid to a mobile device that is running out of energy in urgent circumstances. To facilitate bidirectional WPT with minimum additional cost, a WPT transceiver reconfigurable for performing WPT and wireless power reception (WPR) is provided. The transceiver is reconfigurable between a differential class-D power amplifier (PA) and a full-wave rectifier. A maximum current charging mode (MCCM) is used to maximize a battery-to-battery (B2B) charging efficiency, by directly charging the loading battery with the rectifier, and by powering the PA with the sourcing battery. No output voltage or current regulation is used. Then the number of cascaded charging stages is reduced from five in the conventional design to three.
H01M 10/46 - Accumulators structurally combined with charging apparatus
H02J 7/02 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries for charging batteries from AC mains by converters
H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
H02J 50/12 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling of the resonant type
81.
Multi-band coupling for superconducting qubits based on coplanar cross-shape resonators
Multi-mode resonator is usually used to design broadband bandpass filters and the cross-shape resonator (CSR) is one of its typical types. The possibility of utilizing cross-shape multi-mode resonators is explored as a signal controller for superconducting qubits that are coplanar to the resonator. The multi-mode qubit-resonator coupling facilitates the design of future quantum information processor.
G06N 99/00 - Subject matter not provided for in other groups of this subclass
G06N 10/00 - Quantum computing, i.e. information processing based on quantum-mechanical phenomena
H01L 39/22 - Devices comprising a junction of dissimilar materials, e.g. Josephson-effect devices
B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
H03K 19/195 - Logic circuits, i.e. having at least two inputs acting on one outputInverting circuits using specified components using superconductive devices
82.
Method of mitigating cardiovascular hypertrophy and perivascular fibrosis induced by angiotensin II
Angiotensin II (AngII) has been strongly implicated in hypertension and its complications. Evidence suggests the mechanisms by which angiotensin II (AngII) elevates blood pressure and enhances cardiovascular remodeling and damage may be distinct. In vascular smooth muscle cells, a metaloproteinase ADAM17 mediates epidermal growth factor receptor (EGER) transactivation, which may be responsible for cardiovascular remodeling but not hypertension induced by AngII. Treatment with a human cross-reactive ADAM17 inhibitory antibody (A9B8) also prevented cardiovascular, remodeling and ER stress but not hypertension in C57Bl/6 mice infused with AngII. In vitro data further supported these findings. In conclusion, vascular ADAM17 mediates AngII-induced cardiovascular remodeling via EGFR activation independent of blood pressure regulation. ADAM17 presents a unique therapeutic target for antibodies such as A9B8 for the prevention of hypertensive complications.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
83.
Integrated circuit for simultaneous electrophysiology recording and optogenetic neural control
Various embodiments of the present technology generally relate to a single monolithic IC to perform simultaneous optogenetic neural inhibition and extracellular electrophysiological recording in-vivo. Some embodiments include a low input capacitance (e.g., 9.7 pF) amplifier particularly tailored for the use of high-impedance electrodes to conduct single neuron extracellular recording integrated with programmable high current drivers for optogenetic stimulation or inhibition on the same IC chip. Some embodiments use a noise model to guide the IC design process to obtain parameters for optimal signal-to-noise ratio. The performance of the IC chip was demonstrated on an anesthetized gerbil expressed with inhibitory optogenetic protein (Halorhodopsin). Spontaneous action potentials from the fifth nerve of the brainstem were recorded by the amplifier and were subsequently inhibited by laser illumination. As a result, various embodiments of the IC allow neuroscience research and neural engineering applications to be conducted in an entirely new direction and can potentially be used in treatments for human mental diseases in the future.
H02J 3/18 - Arrangements for adjusting, eliminating or compensating reactive power in networks
H02J 3/01 - Arrangements for reducing harmonics or ripples
H02M 7/537 - Conversion of DC power input into AC power output without possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only, e.g. single switched pulse inverters
The present invention discloses a real-time detection system based on hybrid background modeling for detecting parked vehicles along the side of a road. The hybrid background model consists of three components: 1) a scene background model, 2) a computed restricted area map, and 3) a dynamic threshold curve for vehicles. By exploiting the motion information of normal activity in the scene, we propose a hybrid background model that determines the location of the road, estimates the roadside and generates the adaptive threshold of the vehicle size. The system triggers a notification when a large vehicle-like foreground object has been stationary for more than a pre-set number of video frames (or time). The present invention is tested on the AVSS 2007 PV dataset. The results are satisfactory compared to other state-of-the-art methods.
G06F 3/00 - Input arrangements for transferring data to be processed into a form capable of being handled by the computerOutput arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
Provided is a microfluidic device comprising an incubation layer, the incubation layer including at least one dock, each of the at least one dock defines a stepped tank comprising an upper tank and a lower tank, an inflow channel in fluid communication with the stepped tank for supplying a fluid to the stepped tank, and an outflow channel in fluid communication with the stepped tank for draining the fluid from the stepped tank, wherein the geometry of the upper tank is configured to allow culturing of a fish larva therein, and wherein the geometry of the lower tank is configured to reversibly receive the fish larva from the upper tank and to dock the fish larva at a controlled orientation for imaging or observation.
c) is connected in series with a parallel combination of the first and second branch of circuit. The electronic controller for the TCLC compensator is configured in accordance to the generalized instantaneous reactive power theory for improving the response speed instead of using traditional average reactive power concept.
H02J 3/18 - Arrangements for adjusting, eliminating or compensating reactive power in networks
H02J 3/01 - Arrangements for reducing harmonics or ripples
H02J 3/36 - Arrangements for transfer of electric power between ac networks via a high-tension dc link
H02J 3/26 - Arrangements for eliminating or reducing asymmetry in polyphase networks
H02J 3/00 - Circuit arrangements for ac mains or ac distribution networks
H02M 1/12 - Arrangements for reducing harmonics from AC input or output
H02M 5/44 - Conversion of AC power input into AC power output, e.g. for change of voltage, for change of frequency, for change of number of phases with intermediate conversion into DC by static converters using discharge tubes or semiconductor devices to convert the intermediate DC into AC
88.
Limit cycle oscillation reduction for digital low dropout regulators
A method achieves minimum limit cycle oscillation (LCO) amplitude of a digital low dropout regulator (D-LDO) by adding auxiliary unit power transistors in parallel with the main PMOS array with selected unit strength and LCO mode. An improved D-LDO with reduced LCO amplitude includes an auxiliary power transistor array in selected strength driven by an output of a comparator in parallel with a main power transistor array.
G05F 1/00 - Automatic systems in which deviations of an electric quantity from one or more predetermined values are detected at the output of the system and fed back to a device within the system to restore the detected quantity to its predetermined value or values, i.e. retroactive systems
G05F 1/565 - Regulating voltage or current wherein the variable actually regulated by the final control device is DC using semiconductor devices in series with the load as final control devices sensing a condition of the system or its load in addition to means responsive to deviations in the output of the system, e.g. current, voltage, power factor
G05F 1/46 - Regulating voltage or current wherein the variable actually regulated by the final control device is DC
G11C 19/28 - Digital stores in which the information is moved stepwise, e.g. shift registers using semiconductor elements
This invention is directed to novel compounds isolated or derived from Alpiniae oxyphyllae fructus, chemically synthesized novel compounds, methods of preparing the novel compounds and uses thereof as neuroprotectants or drugs for treating neurodegenerative diseases such as Parkinson's disease.
C07C 59/52 - Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
C07C 51/47 - SeparationPurificationStabilisationUse of additives by solid-liquid treatmentSeparationPurificationStabilisationUse of additives by chemisorption
C07C 59/90 - Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
C07C 59/54 - Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
C07C 51/347 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups
90.
Iridium(III)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent
Kaohsiung Medical University (Taiwan, Province of China)
Inventor
Leung, Chung-Hang
Zhong, Hai-Jing
Ma, Dik-Lung
Wang, Hui-Min
Abstract
Bromodomain-containing protein 4 (BRI)) has recently emerged as an attractive epigenetic target for anticancer therapy. Iridium(III) complexes are useful as irreversible inhibitor of BRD4. Complex 1a of the formula:
is particularly useful.
A mixed signal controller for a power quality compensator includes an analog circuit, an analog-to-digital converter (ADC), and a digital circuit. The analog circuit amplifies an input signal from the power quality compensator by a gain factor and outputs an analog signal, which is converted to a digital signal by the ADC. The digital circuit receives the digital signal, calculates the reference compensating current of each phase and then generates a trigger signal via hysteresis PWM to the power quality compensator. The digital circuit includes an evaluation circuit that calculates a value of the system total harmonic distortion after the power quality compensator compensates power and adjusts the gain factor when the value of the system total harmonic distortion reaches a predetermined threshold.
A palm-size portable μNMR relaxometer system for performing multi-step multi-sample chemical/biological assays, comprising a PCB having a CMOS μNMR transceiver and a DMF device integrated thereon. A portable magnet has an inner gap configured to at least partially receive the DMF device. The DMF device comprises a platform of electrodes including a sensing site and receives one or more samples for analysis at an electrode and automatically transports the one or more samples on individual paths sequentially to the sensing site, for performing sensing on each sample sequentially. A Butterfly coil disposed on the PCB and underneath the DMF device and is at least partially received in the inner gap. The Butterfly coil excites the sample at the μNMR sensing site by transducing a magnetic field produced at the sensing site to an electrical signal which is processed by the CMOS μNMR transceiver to produce an analytical signal.
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
G01R 33/44 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
A luminescent Ir(III) complex is used to develop a label-free G-quadruplex-based assay for lead ions in liquid or solution. In particular, the present invention describes method for monitoring lead ion concentration in water.
G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators
94.
Compliant gripper with integrated position and grasping/interaction force sensing for microassembly
A compliant gripper with integrated position and force sensors dedicated to automated micro-assembly tasks. The gripper possesses a larger gripping range with a bidirectional drive, and is capable of detecting grasping force and environmental interaction forces in horizontal and vertical axes. The gripper has a compliant rotary flexure bearing. The gripper further has a compliant mechanism with two-stage stiffness designed to provide force sensing with dual sensitivities in two measuring ranges to accommodate the grasping of objects with different sizes. The dual-sensitivity, dual-range force sensor provides finer and coarser force sensing in a small and large ranges, respectively. Analytical models are derived to predict the grasping range, force sensing sensitivities, and force measuring ranges. These models are verified by conducting finite-element analysis simulations.
Disclosed are compositions and methods for treatment of a disease or disorder of the eye and adnexa of the eye, including dry eye disease and Sjögren's syndrome, by administering a composition comprising an indole and a flavonoid either as an admixture or as a synthetic heterodimer thereof.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
96.
Method for antagonizing STAT3 dimerization and compounds for use therein
Kaohsiung Medical University (Taiwan, Province of China)
Inventor
Leung, Chung-Hang
Ma, Dik-Lung
Wang, Hui-Min
Abstract
A compound of the formula:
Also, a method for antagonizing STAT3 dimerization in a patient in need thereof which by administering to such patient a therapeutically acceptable dose of the compound of Formula I. Further, a method for treating a cancer patient in need thereof by administering a therapeutically effective dose of the compound of Formula I.
According to one aspect of the present disclosure, a control-engaged electrode-driving method for droplet actuation is provided. The method includes, a first voltage is provided to a first electrode for licking off a droplet. A second voltage is naturally discharged to a third voltage for maintaining a droplet movement. A fourth voltage is provided to the first electrode for accelerating the droplet. Naturally discharging from the second voltage to the third voltage and providing the fourth voltage to the first electrode are repeated. The first voltage is provided to a second electrode when a centroid of the droplet reaching a centroid of the first electrode. Naturally discharging from the second voltage to the third voltage and providing the fourth voltage to the second electrode are repeated.
According to one aspect of the present disclosure, a digital microfluidic system is provided. The digital microfluidic system includes a device, a control electronics, a field programmed gate array (FPGA), and a computer. The device includes a droplet on an electrode array, where the electrode array includes a plurality of electrodes. The control electronics connects to the device and provides an actuation pulse to the electrodes, where the control electronics generates a capacitance-derived frequency signal. The FPGA connects to the control electronics and collects the capacitance-derived frequency signal. The computer connects to the FPGA, the computer uses a frequency of the capacitance-derived frequency signal to calculate a precise droplet position and generates a duration voltage signal.
G01N 27/27 - Association of two or more measuring systems or cells, each measuring a different parameter, where the measurement results may be either used independently, the systems or cells being physically associated, or combined to produce a value for a further parameter
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
According to one aspect of the present disclosure, a control-engaged electrode-driving method for droplet actuation is provided. The method includes, a first pulse is provided to a first electrode for kicking off a droplet till a centroid of the droplet reaching a centroid of the first electrode. A second pulse is provided to a second electrode when a leading edge of the droplet reaching the second electrode.
The present invention discloses a gain-boosted n-path passive-mixer-first receiver. According to another aspect of the present disclosure, a gain-boosted n-path passive-mixer-first receiver is provided. The receiver includes a number n of switch-capacitor (sc) sets, a resistor, and a transconductance amplifier. The sc sets connect in parallel, and the sc sets have a first node and a second node. The resistor connects to the first node. The transconductance amplifier connects to the resistor and the second node.
H03B 5/12 - Generation of oscillations using amplifier with regenerative feedback from output to input with frequency-determining element comprising lumped inductance and capacitance active element in amplifier being semiconductor device
patents
